ProCE Banner Activity

How I Use Checkpoint Inhibitors in Later-line Advanced Gastric/GEJ Cancers

Clinical Thought
Which of our patients with advanced gastric/GEJ cancers are most likely to benefit from later-line treatment with PD-1 inhibitors? Here’s my take on applying the latest evidence to the clinic.

Released: July 18, 2019

Expiration: July 16, 2020

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb

Faculty Disclosure

Primary Author

Tanios Bekaii-Saab, MD, FACP

David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research I
Chair and Consultant, Division of Hematology and Medical Oncology
Professor
Mayo Clinic College of Medicine and Science
Mayo Clinic in Arizona
Phoenix, Arizona

Tanios Bekaii-Saab, MD, FACP, has disclosed that he has received consulting fees from Armo, AstraZeneca, Imugene, Immuneering, and Pieris.